BTX Brooklyn ImmunoTherapeutics, Inc. Stock Quote

BTX [AMEX]

Index	-	P/E	-	EPS (ttm)	-3.04	Insider Own	0.50%	Shs Outstand	1.48M	Perf Week	-2.78%
Market Cap	254.92M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	-	Perf Month	13.76%
Income	-4.40M	PEG	-	EPS next Q	-	Inst Own	0.20%	Short Float	-	Perf Quarter	60.88%
Sales	5.80M	P/S	43.95	EPS this Y	-110.90%	Inst Trans	-70.04%	Short Ratio	0.04	Perf Half Y	66.45%
Book/sh	0.58	P/B	13.26	EPS next Y	-	ROA	-66.60%	Target Price	-	Perf Year	217.77%
Cash/sh	0.02	P/C	318.65	EPS next 5Y	-	ROE	-248.90%	52W Range	1.88 - 15.52	Perf YTD	71.65%
Dividend	-	P/FCF	-	EPS past 5Y	17.40%	ROI	-217.30%	52W High	-50.45%	Beta	0.58
Dividend %	-	Quick Ratio	0.70	Sales past 5Y	-25.00%	Gross Margin	49.90%	52W Low	309.04%	ATR	1.30
Employees	22	Current Ratio	0.70	Sales Q/Q	-76.90%	Oper. Margin	-	RSI (14)	57.13	Volatility	20.21% 19.34%
Optionable	No	Debt/Eq	2.22	EPS Q/Q	122.50%	Profit Margin	-76.40%	Rel Volume	0.32	Prev Close	7.94
Shortable	No	LT Debt/Eq	0.56	Earnings	-	Payout	-	Avg Volume	1.86M	Price	7.69
Recom	-	SMA20	36.38%	SMA50	5.57%	SMA200	50.42%	Volume	588,733	Change	-3.15%

Apr-19-21 04:10PM	Brooklyn ImmunoTherapeutics Reports Inducement Grants Business Wire
Apr-15-21 04:10PM	Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders Business Wire
08:00AM	Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc. Business Wire
Apr-06-21 08:00AM	Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc. Business Wire +29.98%
Mar-25-21 05:20PM	Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime Business Wire
Dec-14-20 08:44AM	Is the Options Market Predicting a Spike in Lineage Cell Therapeutics (LCTX) Stock? Zacks
Nov-04-20 06:05PM	Lineage Cell (LCTX) Reports Q3 Loss, Lags Revenue Estimates Zacks +6.63%
May-08-20 10:37PM	Edited Transcript of BTX earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience